Alexandra M. Poos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra M. Poos has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Niels Weinhold
Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
10 shared publications - Bachisio Ziccheddu
Sheila and David Fuente Cancer Biology Graduate Program, University of Miami Miller School of Medicine, Miami, Florida
9 shared publications - Benjamin Diamond
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
9 shared publications - Faith E. Davies
Perlmutter Cancer Center, NYU Langone Health, New York, NY
9 shared publications - Francesco Maura
Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
9 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Bioinformatic pipeline details
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Bioinformatic pipeline details
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Figure 1. Overview of bioinformatic workflow for each module of the Myeloma Genome Pipeline 1000 (MGP1000). Supplementary Figure 2. Bar plot highlighting the cases where the self-identified race did not match the ancestry. Supplementary Figure 3. Comparison of copy number variation (CNV) and single nucleotide variants (SNV) between African-dominant (AFR) and European-dominant (EUR) admixture clusters. Supplementary Figure 4. Comparison of tumor coverage and purity stratified by admixture cluster assignment. Supplementary Figure 5. Comparison of age and total mutational burden (TMB) stratified by admixture cluster assignment. Supplementary Figure 6. The number of kataegis foci are associated with admixture groups. Supplementary Figure 7. Principal component analysis (PCA) plots generated via EIGENSTRAT for the AFR Dominant population. Supplementary Figure 8. Haplotype distribution at each of 6 significantly distributed SNPs from those comprising the PRS. Supplementary Figure 9. Relationship between polygenic risk score (PRS), APOBEC activity and APOBEC SNP genotypes. Supplementary Figure 10. APOBEC (SBS2/SBS13) contribution by Admixture group and pre/post-gain stage.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Figure 1. Overview of bioinformatic workflow for each module of the Myeloma Genome Pipeline 1000 (MGP1000). Supplementary Figure 2. Bar plot highlighting the cases where the self-identified race did not match the ancestry. Supplementary Figure 3. Comparison of copy number variation (CNV) and single nucleotide variants (SNV) between African-dominant (AFR) and European-dominant (EUR) admixture clusters. Supplementary Figure 4. Comparison of tumor coverage and purity stratified by admixture cluster assignment. Supplementary Figure 5. Comparison of age and total mutational burden (TMB) stratified by admixture cluster assignment. Supplementary Figure 6. The number of kataegis foci are associated with admixture groups. Supplementary Figure 7. Principal component analysis (PCA) plots generated via EIGENSTRAT for the AFR Dominant population. Supplementary Figure 8. Haplotype distribution at each of 6 significantly distributed SNPs from those comprising the PRS. Supplementary Figure 9. Relationship between polygenic risk score (PRS), APOBEC activity and APOBEC SNP genotypes. Supplementary Figure 10. APOBEC (SBS2/SBS13) contribution by Admixture group and pre/post-gain stage.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Table 1. Summary of the source of data included in this study. Supplementary Table 2. Summary of demographic and genomic metadata variables collected for patients included in this study. Supplementary Table 3. Comparison of genomic classification events (n = 130) between EUR and AFR Dominant populations in NDMM patients with high ancestry contribution (EUR >0.8 or AFR >0.8). Supplementary Table 4. Comparison of genomic classification events (n = 130) using AFR ancestry as a linear value (linear regression model). Supplementary Table 5. Comparison of genomic classification events (n = 130) between EUR and AFR dominant populations in NDMM patients with high tumor purity (> 0.5) and high coverage (> 40x). Supplementary Table 6. Comparison of genomic classification events between the P1000 EUR group and the GMMG-HD6 cohort. Supplementary Table 7. Odds-ratio comparison for risk of developing multiple myeloma or myeloma precursor conditions for 31 germline SNPs. Supplementary Table 8. Proportion of germline SNPs in APOBEC across AFR and EUR in NDMM. Supplementary Table 9. Subanalysis for comparison of association of APOBEC mutational signatures (SBS2/SBS13) with 31 germline SNPs based on ancestry cluster (EUR, AFR). Supplementary Table 10. The age of multiple myeloma diagnosis from the SEER database.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Table 1. Summary of the source of data included in this study. Supplementary Table 2. Summary of demographic and genomic metadata variables collected for patients included in this study. Supplementary Table 3. Comparison of genomic classification events (n = 130) between EUR and AFR Dominant populations in NDMM patients with high ancestry contribution (EUR >0.8 or AFR >0.8). Supplementary Table 4. Comparison of genomic classification events (n = 130) using AFR ancestry as a linear value (linear regression model). Supplementary Table 5. Comparison of genomic classification events (n = 130) between EUR and AFR dominant populations in NDMM patients with high tumor purity (> 0.5) and high coverage (> 40x). Supplementary Table 6. Comparison of genomic classification events between the P1000 EUR group and the GMMG-HD6 cohort. Supplementary Table 7. Odds-ratio comparison for risk of developing multiple myeloma or myeloma precursor conditions for 31 germline SNPs. Supplementary Table 8. Proportion of germline SNPs in APOBEC across AFR and EUR in NDMM. Supplementary Table 9. Subanalysis for comparison of association of APOBEC mutational signatures (SBS2/SBS13) with 31 germline SNPs based on ancestry cluster (EUR, AFR). Supplementary Table 10. The age of multiple myeloma diagnosis from the SEER database.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 742-758
Genomic features do not account for differences in multiple myeloma risk by ancestry
Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 742-758
Genomic features do not account for differences in multiple myeloma risk by ancestry
Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.
- 22 May 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (5) , 450-463
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. In this study, we interrogated 580 whole-genome sequence (WGS) samples from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose–response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode, we demonstrate that a single RT-surviving cell may seed distant relapse. Significance: RT and the ID8 indel signature are related, but their genomic impact on hematologic malignancies is unclear. Leveraging WGS, we linked ID8 to both RT and mutagenic chemotherapy and validated that platinum can induce ID8. We used ID8 as a genomic barcode to reveal that RT-resistant cells may seed systemic relapse.
- 22 May 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (5) , 450-463
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. In this study, we interrogated 580 whole-genome sequence (WGS) samples from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose–response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode, we demonstrate that a single RT-surviving cell may seed distant relapse. Significance: RT and the ID8 indel signature are related, but their genomic impact on hematologic malignancies is unclear. Leveraging WGS, we linked ID8 to both RT and mutagenic chemotherapy and validated that platinum can induce ID8. We used ID8 as a genomic barcode to reveal that RT-resistant cells may seed systemic relapse.
- Open Access
- 28 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (104) , eadp6667
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However, the processes underlying bone marrow independence and their consequences for immune control remain poorly understood. Here, we conducted single-cell and spatial multiomics analyses of bone marrow–confined intramedullary disease and paired breakout lesions that disrupt the cortical bone. These analyses revealed a distinct cellular microenvironment and architectural features of breakout lesions, characterized by extensive areas of malignant plasma cells interspersed with lesion-specific solitary natural killer and macrophage populations, as well as focal accumulations of immune cell agglomerates. Within these agglomerates, spatially confined T cell clones expanded alongside various immune cells, coinciding with the local genomic evolution of tumor cells. These analyses identify breakout lesions as a hotspot for tumor-immune cell interactions and diversification, representing a key event in myeloma pathogenesis.
- 28 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (104) , eadp6667
Open AccessBone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However, the processes underlying bone marrow independence and their consequences for immune control remain poorly understood. Here, we conducted single-cell and spatial multiomics analyses of bone marrow–confined intramedullary disease and paired breakout lesions that disrupt the cortical bone. These analyses revealed a distinct cellular microenvironment and architectural features of breakout lesions, characterized by extensive areas of malignant plasma cells interspersed with lesion-specific solitary natural killer and macrophage populations, as well as focal accumulations of immune cell agglomerates. Within these agglomerates, spatially confined T cell clones expanded alongside various immune cells, coinciding with the local genomic evolution of tumor cells. These analyses identify breakout lesions as a hotspot for tumor-immune cell interactions and diversification, representing a key event in myeloma pathogenesis.